Hyperinsulinemic hypoglycemia in a newborn infant with trisomy 13
Takuya Tamame,N. Hori,Hidekazu Homma,R. Yoshida,M. Inokuchi,K. Kosaki,Takao Takahashi,T. Hasegawa
DOI: https://doi.org/10.1002/ajmg.a.30147
2004-09-01
Abstract:Trisomy 13 is the third most common trisomic disorder in human livebirths. The prevalence is about 1 in 5,000 births with high infant mortality. We describe a newborn infant with trisomy 13, who developed hyperinsulinemic hypoglycemia treated with diazoxide. The Japanese boy was the third child of a 34-year-old mother and a 34-year-old father. He was born by Cesarian section at 35 weeks of gestation due to late deceleration on non-stress test. His birth weight was 2,048 g (<10th centile), length 46.5 cm (10–50th centile), and OFC 31.0 cm (50–90th centile). Apgar scores were 1 and 2 at 1 and 5 min, respectively. Physical examination showed the following findings: frontal bossing, blepharophimosis, corneal clouding, right low-set ear, hypoplastic right earlobe, thin upper lip, hypoplastic philtrum, systolic heart murmur, overlapping fingers, posterior heel prominence, scrotalization of penis, and bilateral unpalpable testes. Chromosome analysis showed a 47,XY,þ13 karyotype. Blood glucose level at birth was 65 mg/dl. After birth (1 hr), his general activity was getting poor with blood glucose level of <40 mg/dl. As twice injections of 2 ml/kg of 20% glucose failed to increase his blood glucose level, continuous glucose infusion was introduced with the 5.0 mg/kg/min infusion rate. In total, 23 mg/kg/min of glucose infusion rate was needed to keep a blood glucose level of 80–90 mg/dl. On the 11th day, hypoglycemia (23 mg/dl blood glucose) was induced when the glucose infusion rate was decreased to 12 mg/kg/min. At that time, serum immunoreactive insulin level (24 IU/ml) was high (normal value, 2–10 IU/ml) together with relatively low free fatty acid (0.33 mEq/L; normal, 0.30–1.00 mEq/L) and low total ketone bodies (15 mmol/L; normal value, 26–122 mmol/L). Diazoxide (10 mg/kg/day) was administered since the 12th day and the glucose infusion rate was gradually decreased. On the 27th day, intravenous glucose infusion was discontinued without hypoglycemia. Judging from all these findings, the diagnosis of hyperinsulinemic hypoglycemia was convincing. It is plausible that hyperinsulinemic hypoglycemia is one of clinical manifestations of trisomy 13, although the possibility of an incidental complication cannot be ruled out. A review of the literature of trisomy 13 revealed two cases of hyperinsulinemic hypoglycemia. A female infant with mosaic trisomy 13 reported by Smith and Giacoia [1985] became very jittery with unmeasurable blood glucose 12 hr after birth, and when blood glucose level was 32 and 26 mg/dl, serum immunreactive insulin level became high, being 41 and 31 IU/ml, respectively. A very high glucose infusion rate (22 mg/kg/min) was also required in this patient to keep normoglycemia for the first 19 days. The other case was a female infant with trisomy 13 reported by Bellaton et al. [2002], developed hypoglycemia (blood glucose lavel, 12 mg/dl) without ketonuria immediately after birth and needed a very high glucose infusion rate (22 mg/ kg/min) to keep normoglycemia. In all these three cases, symptomatic hypoglycemia was evident within 12 hr after birth. The pathogenesis of hyperinsulinemic hypoglycemia in trisomy 13 remains unknown. Overdosage of certain gene(s) may lead to hyperinsulinism. Such candidate genes include the insulin promoter factor-1 gene (IPF1) [MIM 600733] located at 13q12.2, which binds the specific sequence within the promoter region of the insulin gene and activates its transcription [Ohlsson et al., 1993], and the caudal-type homeo box transcription factor 2 gene (CDX2) [MIM 600297] located at 13q12.3, encoding a homeodomein protein that binds an A/T-rich sequence in the insulin promoter and stimulates its transcription [German et al., 1992]. In view of the complexity of hyperinsulinemic hypoglycemia, its onset is likely determined by polygenes. This may explain why most patients with trisomy 13 do not develop symptomatic hyperinsulinemic hypoglycemia. Ductuloinsular complexes (incorporation of ducts into islets of Langerhans or the close association of endocrine cells with small knots of ductules) have been described in the pancreatic pathology in some patients with trisomy 13, which was interpreted as nesidioblastosis [Hashida et al., 1983; Moerman et al., 1988]. Nesidioblastosis has long been considered as the original lesion for the diffuse form of hyperinsulinism, although it is not specific.